- ￥880 - 1320
- CUSABIO
- CN
- CSB-PA004092
- 2025年07月10日
- WB, IF, ELISA; WB:1:500-1:2000, IF:1:200-1:1000, ELISA:1:20000
- Rabbit
- Human
企业认证
相关产品推荐更多 >
CHRNA2抗体CHRNA2一抗抗体Nicotinic Acetylcholine Receptor alpha 2 antibody抗体CHRNA2 Antibody抗体
￥1100
TRADD抗体TRADD兔多抗抗体Tumor necrosis factor receptor type 1-associated DEATH domain protein antibody抗体TRADD Antibody, HRP conjugated抗体
￥880
ZNF280A抗体ZNF280A一抗抗体ZNF636 antibody抗体ZNF280A Antibody抗体
￥880
UCP2抗体UCP2一抗抗体UCPH抗体UCP2 Antibody抗体
￥1100
CCL17抗体CCL17兔多抗抗体Thymus and activation-regulated chemokine antibody抗体CCL17 Antibody, HRP conjugated抗体
￥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Synthesized peptide derived from the N-terminal region of Human Sideroflexin-4.
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
/
- 标记物：
Non-conjugated
- 适应物种：
Human
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
Q6P4A7
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
WB, IF, ELISA; WB:1:500-1:2000, IF:1:200-1:1000, ELISA:1:20000
- 浓度：
>95%,The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- 靶点：
SFXN4
- 抗体英文名：
SFXN4 Antibody
- 抗体名：
SFXN4;BCRM1;Sideroflexin-4;Breast cancer resistance marker 1
- 规格：
100μg/50μg
| 规格： | 100μg | 产品价格： | ￥1320.0 |
|---|---|---|---|
| 规格： | 50μg | 产品价格： | ￥880.0 |
保存缓冲液
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.功能
/风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Multiple drug resistance, mediated by the expression and activity of ABC-transporters, is a major obstacle to antineoplastic therapy. Normal tissue stem cells and their malignant counterparts share MDR transporter activity
the clinical usefulness of urinary β-CF as a tumor marker for nontrophoblastic tumors ( 5 , 6 ). Here, the authors describe the methods to measure urinary β-CF in patients with ovarian cancer. Fig. 1. Two antigenic sites: the first domain
Therapeutic strategies for cancer include chemotherapy, immunotherapy, and radiation. Such therapies result in significant short-term clinical responses; however, relapses and recurrences occur with no treatments. Targeted therapies using
技术资料暂无技术资料 索取技术资料
